GlassScriptPhysician profile
Tony Smitherman
NPI 1578567186
$1,353.28
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $269 · 2020: $343 · 2021: $315 · 2022: $204 · 2023: $223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $223.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $569.06 | 2019-2023 | Mako |
| Pacira Therapeutics, INC. | $283.56 | 2019-2021 | |
| Depuy Synthes Sales INC. | $114.34 | 2020-2023 | Monovisc |
| Heron Therapeutics, INC. | $92.80 | 2022 | |
| Ferring Pharmaceuticals INC. | $54.92 | 2021-2022 | |
| Fx Shoulder Solutions, INC | $36.19 | 2021 | |
| Sanofi Pasteur INC. | $32.63 | 2022 | |
| Ethicon US, LLC | $29.71 | 2021 | |
| Merck Sharp & Dohme LLC | $27.67 | 2022-2023 | Bridion |
| Sanofi-Aventis U.S. LLC | $27.54 | 2023 | |
| Innovation Technologies INC | $19.90 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $18.80 | 2022 | |
| Radius Health, INC. | $18.60 | 2021 | |
| Bioventus LLC | $15.01 | 2020 | |
| Baudax Bio INC. | $12.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tony Smitherman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.